EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland

Sanna Susila iD, Minna Ilmakunnas iD, Jouni Lauronen, Pauli Vuorinen, Susanne Ångerman, Susanna Sainio

Transfusion · 2024

DOI: 10.1111/trf.17700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Sanna Susila und 5 weiteren Autor:innen. Beteiligte Einrichtung: Finnish Red Cross Blood Service, Vantaa, Finland. Hauptthemen laut MEDLINE: ABO Blood-Group System, Rh Isoimmunization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prehospital low‐titer group O whole blood (LTOWB) used for patients with life‐threatening hemorrhage is often RhD positive. The most important complication following RhD alloimmunization is hemolytic disease of the fetus and newborn (HDFN). Preceding clinical use of RhD positive LTOWB, we estimated the risk of HDFN due to LTOWB prehospital transfusion in the Finnish population. Study Design and Methods We collected data on prehospital transfusions in Tampere and Helsinki University Hospital areas. Using the mean of reported alloimmunization rates in trauma studies (24%) and a higher reported rate representing trauma patients of 13–50 years old (42.7%), we estimated the risk of HDFN and extrapolated it to the whole of Finland.

Results

We estimated that in Finland, with the current prehospital transfusion rate we would see 1–3 cases of severe HDFN due to prehospital LTOWB transfusions every 10 years, and fetal death due to HDFN caused by LTOWB transfusion less than once in 100 years.

Discussion

The estimated risk of serious HDFN due to prehospital LTOWB transfusion in the Finnish population is similar to previous estimates. As Finland routinely screens expectant mothers for red blood cell antibodies and as the contemporary treatment of HDFN is very effective, we support the prehospital use of RhD positive LTOWB in all patient groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ABO Blood-Group SystemRh IsoimmunizationAdolescentAdultFemaleHumansInfant, NewbornMaleMiddle AgedYoung AdultBlood TransfusionErythroblastosis, FetalFinlandRh-Hr Blood-Group SystemRisk FactorsTransfusion ReactionHemolysis

Stichwörter der Autor:innen

RhD alloimmunizationhemolytic disease of the fetus and newbornlow‐titer group O whole bloodprehospital

Substanzen

ABO Blood-Group SystemRh-Hr Blood-Group System

Autor:innen und Institutionen

  • Finnish Red Cross Blood Service, Vantaa, Finland.
  • Emergency Medical Service and Emergency Department, Päijät-Häme wellbeing services county, Lahti, Finland.
  • Department of Anesthesiology and Intensive Care Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Meilahti Hospital Blood Bank, Department of Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Emergency Medical Services, Centre for Prehospital Emergency Care, Pirkanmaa wellbeing services county, Tampere, Finland.
  • Department of Emergency Medicine and Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

ORCID-Profile: Sanna Susila, Minna Ilmakunnas

Zitieren

APA

Susila, S., Ilmakunnas, M., Lauronen, J., Vuorinen, P., Ångerman, S., & Sainio, S. (2024). Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland. Transfusion. https://doi.org/10.1111/trf.17700

Vancouver

Susila S, Ilmakunnas M, Lauronen J, Vuorinen P, Ångerman S, Sainio S. Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland. Transfusion. 2024. doi:10.1111/trf.17700

BibTeX
@article{Susila2024,
  author = {Susila, Sanna and Ilmakunnas, Minna and Lauronen, Jouni and Vuorinen, Pauli and Ångerman, Susanne and Sainio, Susanna},
  title = {Low titer group O whole blood and risk of RhD alloimmunization: Rationale for use in Finland},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17700}
}
Kostenlos starten →